Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(13%)
Results Posted
25%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
2
25%
Ph early_phase_1
1
13%
Ph phase_3
1
13%
Ph phase_1
2
25%
Ph not_applicable
1
13%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(2)

Detailed Status

Completed4
unknown2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 31 (14.3%)
N/A1 (14.3%)

Trials by Status

terminated113%
completed450%
recruiting113%
unknown225%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

Personalized Therapies in Inflammatory Complex Disease

NCT03651518
terminatedphase_1

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583
completedphase_3

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

NCT01705756
unknownphase_1

Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients

NCT04691765
completedearly_phase_1

IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

NCT04136028
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03651518Phase 2

Personalized Therapies in Inflammatory Complex Disease

Recruiting
NCT02780583Phase 1

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

Terminated
NCT01705756Phase 3

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Completed
NCT04691765Phase 1

Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients

Unknown
NCT04136028Early Phase 1

IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

Completed
NCT00420290Not Applicable

Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients

Completed
NCT01285245Phase 2

Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus

Unknown
NCT00121056

REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8